Sunesis to Host Conference Call on November 2nd to Discuss Third Quarter 2017 Financial Results and Recent Highlights
October 27 2017 - 6:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it
will host a conference call on Thursday, November 2, 2017 at 2:00
p.m. Eastern Time to discuss corporate updates and financial
results for the third quarter ended September 30, 2017.
The call can be accessed by dialing (844)
269-7720 (U.S. and Canada) or (574) 990-1148 (international), and
entering passcode 1071001.
To access the live audio webcast, or the
subsequent archived recording, visit the "Investors and Media -
Calendar of Events" section of the Sunesis website at
http://ir.sunesis.com. The webcast will be recorded and available
for replay on the company's website for two weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company focused
on the development and commercialization of new oncology
therapeutics for the future treatment of solid and hematologic
cancers. Sunesis has built an experienced cancer drug development
organization committed to improving the lives of people with
cancer. The Company is focused on advancing its novel
kinase-inhibitor pipeline, with an emphasis on establishing proof
of concept that its oral non-covalent BTK-inhibitor, SNS-062,
treats ibrutinib-resistant chronic lymphocytic leukemia. SNS-062 is
currently being evaluated in a Phase 1b/2, open-label,
sequential-group, dose-escalation and cohort-expansion study in
adults with chronic lymphocytic leukemia, Waldenstrom’s
macroglobulinemia and mantle cell lymphoma that have progressed
after prior therapies. Beyond the development of SNS-062, the
Company has two other kinase inhibitor programs, including the
Takeda-partnered pan-RAF inhibitor TAK-580, which is in a Phase 2
solid tumor trial, and its proprietary preclinical PDK1 inhibitor
SNS-510, which is completing non GLP toxicology studies.
For additional information on Sunesis, please
visit http://www.sunesis.com.
SUNESIS and the logos are trademarks
of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries: Maeve Conneighton
Argot Partners 212-600-1902
Dan Swisher Sunesis Pharmaceuticals Inc.
650-266-3715
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles